Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Accumulated Expenses (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Accumulated Expenses over the past 10 years, most recently at $11.0 million for Q4 2023.

  • For Q4 2023, Accumulated Expenses rose 395.74% year-over-year to $11.0 million; the TTM value through Dec 2023 reached $11.0 million, up 395.74%, while the annual FY2023 figure was $11.0 million, 395.74% up from the prior year.
  • Accumulated Expenses for Q4 2023 was $11.0 million at Corbus Pharmaceuticals Holdings, up from $1.7 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $28.6 million in Q3 2020 and troughed at $1.7 million in Q3 2023.
  • A 5-year average of $10.2 million and a median of $5.1 million in 2022 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: soared 1979.0% in 2019 and later tumbled 88.33% in 2021.
  • Year by year, Accumulated Expenses stood at $3.7 million in 2019, then soared by 499.1% to $22.0 million in 2020, then tumbled by 54.13% to $10.1 million in 2021, then tumbled by 77.96% to $2.2 million in 2022, then surged by 395.74% to $11.0 million in 2023.
  • Business Quant data shows Accumulated Expenses for CRBP at $11.0 million in Q4 2023, $1.7 million in Q3 2023, and $2.2 million in Q4 2022.